Shots:

• Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial
• The focus of the agreement is to discover targets and develop treatments- with combined techniques of the company in pulmonary disorders including idiopathic pulmonary fibrosis (IPF)
• In 2014- Bayer and Kyoto University's Office of Society-Academia Collaboration for Innovation (KU-SACI) collaborated to jointly explore candidates for certain research projects in areas cardiology & oncology including hematology- gynecology- and ophthalmology

Ref: Bayer | Image: Bayer